title: Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.
authors.affiliation: University of Milan-Bicocca, Monza, Italy carlo.gambacorti@unimib.it.
authors.forename: Carlo
authors.initials: C
authors.lastname: Gambacorti-Passerini
authors.forename: Lara
authors.initials: L
authors.lastname: Mussolin
authors.forename: Laurence
authors.initials: L
authors.lastname: Brugieres
mesh_terms: D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D002675:Child, Preschool; D000077547:Crizotinib; D005260:Female; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy*; D016133:Polymerase Chain Reaction; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000097:blood; D020794:Receptor Protein-Tyrosine Kinases / Q000097:blood / Q000235:genetics; D012008:Recurrence
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D012333:RNA, Messenger; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases